HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues

The prognostic role of adjacent nontumor tissue in hepatocellular carcinoma (HCC) patients is still not clear. The activity changes of immunologic and hallmark gene sets in adjacent nontumor tissues may substantially impact on prognosis by affecting proliferation of liver cells and colonization of circulating tumor cells after HCC treatment measures such as hepatectomy. We aimed to identify HCC subtypes and prognostic gene sets based on the activity changes of gene sets in tumor and nontumor tissues, to improve patient outcomes. We comprehensively revealed the activity changes of immunologic and hallmark gene sets in HCC and nontumor samples by gene set variation analysis (GSVA), and identified three clinically relevant subtypes of HCC by nonnegative matrix factorization method (NMF). Patients with subtype 1 had good overall survival, whereas those with subtype 2 and subtype 3 had poor prognosis. Patients with subtype 1 in the validation group also tended to live longer. We also identified three prognostic gene sets in tumor and four prognostic gene sets in nontumor by least absolute shrinkage and selection operator method (LASSO). Interestingly, functional enrichment analysis revealed that in nontumor tissues, genes from four gene sets correlated with immune reaction, cell adhesion, whereas in tumor tissue, genes from three gene sets closely correlated with cell cycle. Our results offer new insights on accurately evaluating prognosis-the important role of gene sets in both tumor and adjacent nontumor tissues, suggesting that when selecting for HCC treatment modality, changes in tumor and nontumor tissues should also be considered, especially after hepatectomy.

[1]  Y. Chong,et al.  NCAPG Is a Promising Therapeutic Target Across Different Tumor Types , 2020, Frontiers in Pharmacology.

[2]  Yuting He,et al.  Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set , 2020, Aging.

[3]  J. Bruix,et al.  Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects , 2010, Seminars in liver disease.

[4]  S. Bae,et al.  Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma , 2020, Cancers.

[5]  H. Lee,et al.  Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma , 2017, Molecular oncology.

[6]  M. Schwartz,et al.  Differences in Surgical Outcomes Between Hepatitis B- and Hepatitis C–Related Hepatocellular Carcinoma: A Retrospective Analysis of a Single North American Center , 2014, Annals of surgery.

[7]  Jiuyong Li,et al.  CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization , 2017, Bioinform..

[8]  S. Imbeaud,et al.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.

[9]  A. Burroughs,et al.  Hepatocellular carcinoma , 2003, The Lancet.

[10]  C. Ishioka,et al.  IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model , 2017, Cancer Immunology, Immunotherapy.

[11]  V. Mazzaferro,et al.  Resection and Liver Transplantation for Hepatocellular Carcinoma , 2005, Seminars in liver disease.

[12]  Jens Nielsen,et al.  Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes , 2018, Proceedings of the National Academy of Sciences.

[13]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[14]  Y. Chong,et al.  The clinical value of Fibulin-1 for prognosis and its prospective mechanism in intrahepatic cholangiocarcinoma. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[15]  Lu He,et al.  EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3 , 2020, Cell Death & Disease.

[16]  H. Benyamini,et al.  Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation. , 2017, Cancer research.

[17]  Stephanie Roessler,et al.  Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. , 2012, Gastroenterology.

[18]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Y. Pomyen,et al.  Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. , 2017, Cancer cell.

[20]  Zhiguang Li,et al.  Paradoxical Roles of IL-4 in Tumor Immunity , 2009, Cellular and Molecular Immunology.

[21]  K. Hui,et al.  MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. , 2016, Cancer letters.

[22]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[23]  X. Sang,et al.  Construction of a lipid metabolism‐related and immune‐associated prognostic signature for hepatocellular carcinoma , 2020, Cancer medicine.

[24]  Hongmei Sun,et al.  Up-regulation of CXCL8 expression is associated with a poor prognosis and enhances tumor cell malignant behaviors in liver cancer , 2020, Bioscience reports.

[25]  A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients , 2020, Journal of translational medicine.

[26]  Jian Zhang,et al.  Multi-omics Analysis of Microenvironment Characteristics and Immune Escape Mechanisms of Hepatocellular Carcinoma , 2019, Front. Oncol..

[27]  D. Fan,et al.  Interleukin 1β-mediated HOXC10 Overexpression Promotes Hepatocellular Carcinoma Metastasis by Upregulating PDPK1 and VASP , 2020, Theranostics.

[28]  K. Liestøl,et al.  Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer , 2019, Modern Pathology.

[29]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[30]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[31]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[32]  Yun Zheng,et al.  A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma , 2020, International journal of biological sciences.